Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: APH
Latest Price: 33.50p  (0,00%)
52-week High: 40.50p
52-week Low: 31.00p
Market Cap: 88.49M
1 year chart More charts
Deal APH Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Alliance Pharma
www.alliancepharma.co.uk
Deal Alliance Pharma Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the...

Read more
Pdf

Alliance Pharma deal an important step towards internationalisation, says City research house

June 10 2013, 11:33am Analysts point out the deal uses the blue-print that underpins company’s success – acquiring prescription drugs that require little or no marketing, but generate a solid revenue stream.

The latest addition to the Alliance Pharma (LON:APH) medicine chest represents an “important step to the internationalisation of the group”, according to the City research house Hardman & Co.

Alliance said last week it will pay US$11.5mln to acquire full ownership of obstetric drug Syntometrine from Swiss giant Novartis.

The speciality pharma group already owns the UK rights to the treatment, which is used in the final stages of labour.

However, Syntometrine sells in around a dozen other major territories, including Australia, South Africa, Malaysia and New Zealand.

Hardman is predicting Alliance’s overseas revenues will rise to around 30% of total sales in 2014, compared with just 18% last year.

Analysts point out the deal uses the blue-print that underpins company’s success – acquiring prescription drugs that require little or no marketing, but generate a solid revenue stream.

Outside the UK Syntometrine generates sales of US$3.2mln. 

Adjusting for inventories, Alliance has paid 3.5 times turnover and 5.5 times earnings for the product, specialist small-cap broker FinnCap said.   

“We believe is a fair price and in line with the multiples we have seen historically for such acquisitions.” 

At 11.30am, the shares were little changed at 37.9 pence, valuing Alliance Pharma at £94mln. In the past year the stock has increased in value by a third.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.